Table 4.
Total body weight gain by obesity class and CYP phenotype in participants prescribed with citalopram, paroxetine, fluoxetine, and sertraline
| Normal and Underweight Group | ||||||||
| CYP2C19 | ||||||||
| Poor/intermediate metabolizer | Normal metabolizer | Rapid/ultra-rapid metabolizer | p-value | |||||
| Citalopram | TBWG 6 mths, % | n = 17 | 4.4 (95% CI 1.9 – 6.8) | n = 26 | 1.5 (95% CI -0.3 – 3.4) | n = 18 | 1.5 (95% CI -0.6 – 3.5) | 0.11 |
| Sertraline | TBWG 6 mths, % | n = 12 | 2.6 (95% CI 0.9 – 4.5) | n = 28 | 1.2 (95% CI -0.8 – 3.1) | n = 19 | 2.7 (95% CI 1.1 – 4.3) | 0.32 |
| CYP2D6 | ||||||||
| Poor/intermediate metabolizer | Normal metabolizer | Rapid/ultra-rapid metabolizer | p-value | |||||
| Paroxetine | TBWG 6 mths, % | n = 33 | 0.6 (95% CI -0.7 – 1.9) | n = 11 | 0.4 (95% CI -2.7 – 3.6) | n = 1 | 3.0 | 0.65 |
| Sertraline | TBWG 6 mths, % | n = 49 | 1.8 (95% CI 0.6 – 3.1) | n = 8 | 1.4 (95% CI -0.5 – 3.4) | n = 2 | 6.7 (95% CI -55.1 – 69.6) | 0.16 |
| Fluoxetine | TBWG 6 mths, % | n = 32 | 1.2 (95% CI -0.3 – 2.7) | n = 14 | 0.9 (95% CI -1.8 – 3.6) | 0.88 | ||
| CYP2C9 | ||||||||
| Poor/intermediate metabolizer | Normal metabolizer | Rapid/ultra-rapid metabolizer | p-value | |||||
| Fluoxetine | TBWG 6 mths, % | n = 26 | 1.9 (95% CI -0.3 – 4.1) | n = 20 | 0.5 (95% CI -1.1 – 2.1) | 0.60 | ||
| Overweight Group | ||||||||
| CYP2C19 | ||||||||
| Poor/intermediate metabolizer | Normal metabolizer | Rapid/ultra-rapid metabolizer | p-value | |||||
| Citalopram | TBWG 6 mths, % | n = 21 | 3.0 (95% CI -0.3 – 6.4) | n = 34 | -0.3 (95% CI -2.1 – 1.5) | n = 24 | 1.3 (95% CI -3.6 – 1.1) | 0.02 |
| Sertraline | TBWG 6 mths, % | n = 19 | 1.5 (95% CI -0.2 – 3.1) | n = 17 | 0.7 (95% CI -0.7 – 2.1) | n = 14 | 2.3 (95% CI 0.6 – 4.1) | 0.44 |
| CYP2D6 | ||||||||
| Poor/intermediate metabolizer | Normal metabolizer | Rapid/ultra-rapid metabolizer | p-value | |||||
| Paroxetine | TBWG 6 mths, % | n = 12 | 1.6 (95% CI -0.8 – 3.9) | n = 12 | 3.5 (95% CI 1.4 – 5.6) | n = 1 | 1.3 | 0.13 |
| Sertraline | TBWG 6 mths, % | n = 40 | 1.3 (95% CI 0.3 – 2.3) | n = 8 | 2.3 (95% CI -0.5 – 3.4) | n = 2 | 0.9 (95% CI -25.0 – 26.8) | 0.69 |
| Fluoxetine | TBWG 6 mths, % | n = 28 | 1.2 (95% CI -2.9 – 0.4) | n = 20 | 0.5 (95% CI -2.2 – 3.2) | 0.21 | ||
| CYP2C9 | ||||||||
| Poor/intermediate metabolizer | Normal metabolizer | Rapid/ultra-rapid metabolizer | p-value | |||||
| Fluoxetine | TBWG 6 mths, % | n = 16 | 0.6 (95% CI -3.3 – 2.1) | n = 32 | 0.5 (95% CI -2.3 – 1.3) | 0.91 | ||
| Obesity Group | ||||||||
| CYP2C19 | ||||||||
| Poor/intermediate metabolizer | Normal metabolizer | Rapid/ultra-rapid metabolizer | p-value | |||||
| Citalopram | TBWG 6 mths, % | n = 20 | 0.8 (95% CI -0.5 – 1.9) | n = 23 | 0.4 (95% CI -0.8 – 1.7) | n = 19 | -0.3 (95% CI -2.7 – 2.2) | 0.18 |
| Sertraline | TBWG 6 mths, % | n = 15 | -0.9 (95% CI -3.1 – 1.2) | n = 21 | -0.7 (95% CI -2.6 – 1.2) | n = 18 | 0.6 (95% CI -1.7 – 2.9) | 0.52 |
| CYP2D6 | ||||||||
| Poor/intermediate metabolizer | Normal metabolizer | Rapid/ultra-rapid metabolizer | p-value | |||||
| Paroxetine | TBWG 6 mths, % | n = 11 | 0.4 (95% CI -0.8 – 1.6) | n = 25 | 0.7 (95% CI -1.3 – 2.6) | n = 1 | 0.4 | 0.98 |
| Sertraline | TBWG 6 mths, % | n = 38 | 0.1 (95% CI -1.6 – 1.3) | n = 15 | 0.3 (95% CI -1.8 – 1.2) | n = 1 | -10.6 | 0.26 |
| Fluoxetine | TBWG 6 mths, % | n = 19 | 0.1 (95% CI -0.9 – 1.0) | n = 76 | -0.9 (95% CI -3.1 – 1.2) | n = 2 | 1.3 (95% CI -33.0 – 35.6) | 0.79 |
| CYP2C9 | ||||||||
| Poor/intermediate metabolizer | Normal metabolizer | Rapid/ultra-rapid metabolizer | p-value | |||||
| Fluoxetine | TBWG 6 mths, % | n = 34 | 0.2 (95% CI -1.1 – 1.5) | n = 63 | -0.3 (95% CI -1.5 – 0.8) | 0.30 | ||
Continuous data are summarized as mean (95% CI)
Abbreviations used: CI confidence interval, TBWG Total Body Weight Gain
p-value: calculated with ANCOVA with metabolizer status and BMI as covariate